The present invention relates to novel synthetic aspirin-mimics that mimic the molecular structure of aspirin, with sulfur to replace oxygen in the key functional groups of aspirin. The novel synthetic aspirin-mimics in this invention integrate multiple features/functions: 1. they are considered as "druggable", as they resemble aspirin in structure 2. they possess the strongest possible capability as scavengers for free radicals 3. they could reinstate some damaged proteins/enzymes via the mechanism of thiol-disulfide exchange 4. they are better chelators to heavy metals and could efficiently remove heavy metals out of body, compared to aspirin. This invention is also directed to novel aspirin-mimics as both drugs and prodrugs, their rational design, their feasible preparation routes by means of synthetic organic chemistry, and their potential therapeutic uses including but not limited to, in treatment and/or prevention of major diseases associated with oxidative stress, such as Alzheimers disease, Parkinsons disease, cancers, diabetes, cardiovascular disease, renal disease, HIV, pain, hypertension, hypercholesterolemia, hyperlipidemia, rheumatoid arthritis, inflammation, aging, stroke, cataract, glaucoma, age-related macular degeneration, depression, acne, etc.La présente invention concerne de nouveaux analogues de synthèse de laspirine qui imitent la structure moléculaire de laspirine, la différence étant que le souffre vient remplacer loxygène dans les groupes fonctionnels clés de laspirine. Les nouveaux analogues de synthèse de laspirine de la présente invention intègrent de multiples caractéristiques/fonctions : 1. ils sont considérés comme des médicaments potentiels, car ils ressemblent à laspirine au niveau de leur structure 2. ils possèdent la plus forte capacité possible en tant que piégeurs de radicaux libres 3. ils pourraient réparer certaines protéines/enzymes endommagées par le mécanisme de léchange thiol-disulfure 4. ils constituent de meilleurs ché
